Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels

References

• Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000–2009. Menopause 2011;18:385–92
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Systematic Rev 2006;(4):CD001500
   Google Scholar
• Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133–9
   PubMed Web of Science ®Google Scholar
• Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195–7
   PubMed Web of Science ®Google Scholar
• Holmgren PA, Lindskog M, von SB. Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy. Maturitas 1989;11:55–63
   PubMed Web of Science ®Google Scholar
• Nilsson K, Heimer G. Low-dose 17 beta-oestradiol during maintenance therapy – a pharmacokinetic and pharmacodynamic study. Maturitas 1995;21:33–8
   PubMed Web of Science ®Google Scholar
• Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 μg 17β-estradiol vaginal tablets. Climacteric 2010;13:219–27
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556–62
   PubMed Web of Science ®Google Scholar
• Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67–76
   PubMed Web of Science ®Google Scholar
• Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84:215–18
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007;16:1713–19
   PubMed Web of Science ®Google Scholar
• Pschera H, Hjerpe A, Carlstrom K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 beta and progesterone in postmenopausal women. Gynecol Obstet Invest 1989;27:204–7
   PubMed Web of Science ®Google Scholar
• Laboratory normal ranges. In Jameson JL, De Groot LJ, eds. Endocriology: Adult and Pediatric, 6th edn. Philadelphia: Saunders, 2010:2812
   Google Scholar
• Schiff I, Tulchinsky D, Ryan KJ. Vaginal absorption of estrone and 17beta-estradiol. Fertil Steril 1977;28:1063–6
   PubMed Web of Science ®Google Scholar
• Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156–61
   PubMed Web of Science ®Google Scholar
• Vartiainen J, Wahlstrom T, Nilsson CG. Effects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas 1993;17:129–37
   PubMed Web of Science ®Google Scholar
• Stumpf PG, Maruca J, Santen RJ, Demers LM. Development of a vaginal ring for achieving physiologic levels of 17 beta-estradiol in hypoestrogenic women. J Clin Endocrinol Metab 1982;54: 208–10
   PubMed Web of Science ®Google Scholar
• Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic BD, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003;82:187–97
   PubMed Web of Science ®Google Scholar
• Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006;13:737–43
   PubMed Web of Science ®Google Scholar
• Naessen T, Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta- estradiol in elderly women. Am J Obstet Gynecol 2002;186: 944–7
   PubMed Web of Science ®Google Scholar
• Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency – a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121–7
   PubMed Web of Science ®Google Scholar
• Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 2001;27:255–60
   PubMed Web of Science ®Google Scholar
• Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991;14:23–31
   PubMed Web of Science ®Google Scholar
• Martin PL, Greaney MO, Burnier AM, Brooks PM, Yen SS, Quigley ME. Estradiol, estrone, and gonadotropin levels after use of vaginal estradiol. Obstet Gynecol 1984;63:441–4
   PubMed Web of Science ®Google Scholar
• van Haaften M, Donker GH, Haspels AA, Thijssen JH. Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications. J Steroid Biochem 1989;33:647–53
   PubMedGoogle Scholar
• Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16:145–54
   PubMed Web of Science ®Google Scholar
• Ulrich LS, Naessen T, Elia D, Goldstein JA, Eugster-Hausmann M; VAG-1748 trial investigators. Endometrial safety of ultra-low-dose Vagifem 10 μg in postmenopausal women with vaginal atrophy. Climacteric 2010;13:228–37
   PubMed Web of Science ®Google Scholar
• Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. Am J Obstet Gynecol 1997;177:115–19
   PubMed Web of Science ®Google Scholar
• Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 2001;86:2757–62
   PubMed Web of Science ®Google Scholar
• Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83–92
   PubMed Web of Science ®Google Scholar
• Dorr MB, Nelson AL, Mayer PR, et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil Steril 2010;94:2365–8
   PubMed Web of Science ®Google Scholar
• Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002;9:179–87
   PubMed Web of Science ®Google Scholar
• Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293–7
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30–6
   PubMed Web of Science ®Google Scholar
• Felding C, Mikkelsen AL, Clausen HV, Loft A, Larsen LG. Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, double-blind trial. Maturitas 1992;15:241–9
   Google Scholar
• Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17:584–7
   PubMed Web of Science ®Google Scholar
• Luisi M, Franchi F, Kicovic PM. A group-comparative study of effects of Ovestin cream versus Premarin cream in post-menopausal women with vaginal atrophy. Maturitas 1980;2:311–19
   PubMed Web of Science ®Google Scholar
• http://rxlist.com/femring-drug/clinical-pharmacology.htm
   Google Scholar
• Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065–79
   PubMed Web of Science ®Google Scholar
• Crandall C. Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. J Women’s Health 2003;12: 723–47
   PubMed Web of Science ®Google Scholar
• Krause M, Wheeler TL, Richter HE, Snyder TE. Systemic effects of vaginally administered estrogen therapy: a review. Female Pelvic Med Reconstr Surg 2010;16:188–95
   PubMedGoogle Scholar
• Al-Azzawi F, Lees B, Thompson J, Stevenson JC. Bone mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. Menopause 2005;12:331–9
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F, Buckler HM, United Kingdom Vaginal Ring Investigator Group. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric 2003;6:118–27
   PubMed Web of Science ®Google Scholar
• Crandall C. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J Women’s Health 2002;11: 857–77
   PubMed Web of Science ®Google Scholar
• Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 903;20:888–902
   Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(Suppl 1):Sl–66
   Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of theWomen’s Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606–16
   PubMed Web of Science ®Google Scholar
• Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer 2005;12:1071–82
   PubMed Web of Science ®Google Scholar
• Key TJ, Appleby PN, Reeves GK, et al.; Endogenous Hormones and Breast Cancer Collaborative Group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011;105:709–22
   PubMed Web of Science ®Google Scholar
• Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996;174:85–92
   PubMed Web of Science ®Google Scholar
• Del PL, Di FR, Cavaliere C, et al. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients? Anti-Cancer Drugs 2013;24:989–98
   PubMed Web of Science ®Google Scholar
• Stute P. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief? Arch Gynecol Obstet 2013;288:1199–201
   PubMed Web of Science ®Google Scholar
• Santen RJ, Lee JS, Wang S, et al. Potential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids 2008;73:1318–21
   PubMed Web of Science ®Google Scholar
• Santen RJ, Demers L, Ohorodnik S, et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007;72:666–71
   PubMed Web of Science ®Google Scholar
• Torres-Santiago L, Mericq V, Taboada M, et al. Metabolic effects of oral versus transdermal 17beta-estradiol (E2): a randomized clinical trial in girls with Turner syndrome. J Clin Endocrinol Metab 2013;98:2716–24
   PubMed Web of Science ®Google Scholar
• Klein KO, Demers LM, Santner SJ, Baron J, Cutler GB, Jr., Santen RJ. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 1995;80:2658–60
   PubMed Web of Science ®Google Scholar